Cargando…

IgA nephropathy after COVID-19 vaccination and analysis of reported cases

BACKGROUND: Immunoglobin A nephropathy (IgAN) is one of the most common forms of chronic glomerulonephritis and has been shown to occur in association with vaccinations. While various vaccines against COVID-19 have become widely used, their side effects, especially on IgAN following COVID-19 vaccine...

Descripción completa

Detalles Bibliográficos
Autores principales: Mima, Akira, Lee, Shinji
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Elsevier 2023
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10266892/
https://www.ncbi.nlm.nih.gov/pubmed/37332909
http://dx.doi.org/10.1016/j.heliyon.2023.e17206
_version_ 1785058829202882560
author Mima, Akira
Lee, Shinji
author_facet Mima, Akira
Lee, Shinji
author_sort Mima, Akira
collection PubMed
description BACKGROUND: Immunoglobin A nephropathy (IgAN) is one of the most common forms of chronic glomerulonephritis and has been shown to occur in association with vaccinations. While various vaccines against COVID-19 have become widely used, their side effects, especially on IgAN following COVID-19 vaccines are still unclear. In this report, we describe the clinical courses and histopathologic findings of a newly diagnosed case of IgAN after receiving the mRNA-1273 (Moderna) COVID-19 vaccination. METHODS: This study presents a case of new-onset IgAN following mRNA-1273 COVID-19 (Moderna) vaccination. In addition, we review and analyze similar cases previously reported in the literature up to October 2022. RESULTS: Of the 52 cases reviewed, including our own, the majority of patients were female, and 64% of patients had initial onset IgAN. The most common manifestation was gross hematuria (87%), other associated symptoms were fever (44%), myalgia (8%), arthralgia (4%), and edema (4%). Many of these cases occurred after receiving Pfizer products as the second vaccination. Oral corticosteroids were used to 16 cases, and steroid pulse therapy was used to treat 7 cases. CONCLUSION: While this is not a controlled study, it is important for physicians to consider the possibility that COVID-19 vaccines may provoke a flare of IgAN. Several therapeutic agents may be useful for treating COVID-19 vaccine-induced IgAN, although a specific mechanism or pathophysiological association cannot be confirmed without further research.
format Online
Article
Text
id pubmed-10266892
institution National Center for Biotechnology Information
language English
publishDate 2023
publisher Elsevier
record_format MEDLINE/PubMed
spelling pubmed-102668922023-06-15 IgA nephropathy after COVID-19 vaccination and analysis of reported cases Mima, Akira Lee, Shinji Heliyon Research Article BACKGROUND: Immunoglobin A nephropathy (IgAN) is one of the most common forms of chronic glomerulonephritis and has been shown to occur in association with vaccinations. While various vaccines against COVID-19 have become widely used, their side effects, especially on IgAN following COVID-19 vaccines are still unclear. In this report, we describe the clinical courses and histopathologic findings of a newly diagnosed case of IgAN after receiving the mRNA-1273 (Moderna) COVID-19 vaccination. METHODS: This study presents a case of new-onset IgAN following mRNA-1273 COVID-19 (Moderna) vaccination. In addition, we review and analyze similar cases previously reported in the literature up to October 2022. RESULTS: Of the 52 cases reviewed, including our own, the majority of patients were female, and 64% of patients had initial onset IgAN. The most common manifestation was gross hematuria (87%), other associated symptoms were fever (44%), myalgia (8%), arthralgia (4%), and edema (4%). Many of these cases occurred after receiving Pfizer products as the second vaccination. Oral corticosteroids were used to 16 cases, and steroid pulse therapy was used to treat 7 cases. CONCLUSION: While this is not a controlled study, it is important for physicians to consider the possibility that COVID-19 vaccines may provoke a flare of IgAN. Several therapeutic agents may be useful for treating COVID-19 vaccine-induced IgAN, although a specific mechanism or pathophysiological association cannot be confirmed without further research. Elsevier 2023-06-15 /pmc/articles/PMC10266892/ /pubmed/37332909 http://dx.doi.org/10.1016/j.heliyon.2023.e17206 Text en © 2023 The Authors https://creativecommons.org/licenses/by-nc-nd/4.0/This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
spellingShingle Research Article
Mima, Akira
Lee, Shinji
IgA nephropathy after COVID-19 vaccination and analysis of reported cases
title IgA nephropathy after COVID-19 vaccination and analysis of reported cases
title_full IgA nephropathy after COVID-19 vaccination and analysis of reported cases
title_fullStr IgA nephropathy after COVID-19 vaccination and analysis of reported cases
title_full_unstemmed IgA nephropathy after COVID-19 vaccination and analysis of reported cases
title_short IgA nephropathy after COVID-19 vaccination and analysis of reported cases
title_sort iga nephropathy after covid-19 vaccination and analysis of reported cases
topic Research Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10266892/
https://www.ncbi.nlm.nih.gov/pubmed/37332909
http://dx.doi.org/10.1016/j.heliyon.2023.e17206
work_keys_str_mv AT mimaakira iganephropathyaftercovid19vaccinationandanalysisofreportedcases
AT leeshinji iganephropathyaftercovid19vaccinationandanalysisofreportedcases